JLB & Associates Inc. Raises Stake in Novo Nordisk A/S (NYSE:NVO)

JLB & Associates Inc. boosted its holdings in Novo Nordisk A/S (NYSE:NVO - Free Report) by 2.3% during the 1st quarter, according to its most recent disclosure with the SEC. The firm owned 219,239 shares of the company's stock after buying an additional 4,874 shares during the period. Novo Nordisk A/S makes up about 2.1% of JLB & Associates Inc.'s investment portfolio, making the stock its 20th largest position. JLB & Associates Inc.'s holdings in Novo Nordisk A/S were worth $15,224,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. Revolve Wealth Partners LLC raised its holdings in shares of Novo Nordisk A/S by 8.7% during the 4th quarter. Revolve Wealth Partners LLC now owns 2,490 shares of the company's stock valued at $214,000 after buying an additional 200 shares during the period. Legacy Capital Wealth Partners LLC raised its stake in shares of Novo Nordisk A/S by 10.4% during the fourth quarter. Legacy Capital Wealth Partners LLC now owns 5,337 shares of the company's stock valued at $459,000 after purchasing an additional 504 shares during the period. Allworth Financial LP raised its stake in shares of Novo Nordisk A/S by 6.0% during the fourth quarter. Allworth Financial LP now owns 33,399 shares of the company's stock valued at $2,691,000 after purchasing an additional 1,897 shares during the period. Sheaff Brock Investment Advisors LLC lifted its position in shares of Novo Nordisk A/S by 16.1% during the fourth quarter. Sheaff Brock Investment Advisors LLC now owns 4,027 shares of the company's stock worth $346,000 after purchasing an additional 557 shares in the last quarter. Finally, Valmark Advisers Inc. boosted its stake in shares of Novo Nordisk A/S by 2.1% in the fourth quarter. Valmark Advisers Inc. now owns 6,627 shares of the company's stock valued at $570,000 after purchasing an additional 136 shares during the period. 11.54% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research firms recently issued reports on NVO. Hsbc Global Res raised shares of Novo Nordisk A/S to a "strong-buy" rating in a research note on Monday, April 28th. Stifel Nicolaus downgraded Novo Nordisk A/S from a "buy" rating to a "hold" rating in a research note on Monday, March 3rd. BMO Capital Markets reiterated a "market perform" rating and issued a $64.00 price target (down previously from $105.00) on shares of Novo Nordisk A/S in a research note on Thursday, April 17th. Dbs Bank lowered Novo Nordisk A/S to a "sell" rating in a research note on Friday, April 25th. Finally, Kepler Capital Markets upgraded Novo Nordisk A/S from a "hold" rating to a "buy" rating in a report on Thursday, March 13th. Two equities research analysts have rated the stock with a sell rating, five have given a hold rating, four have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, Novo Nordisk A/S currently has a consensus rating of "Hold" and an average price target of $112.00.

Novo Nordisk A/S Stock Performance

Shares of NVO stock opened at $77.02 on Tuesday. The stock has a market capitalization of $345.62 billion, a price-to-earnings ratio of 23.41, a PEG ratio of 0.90 and a beta of 0.66. Novo Nordisk A/S has a one year low of $57.00 and a one year high of $148.15. The company's 50-day simple moving average is $67.61 and its 200-day simple moving average is $79.24. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.55 and a current ratio of 0.74.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last released its earnings results on Wednesday, May 7th. The company reported $0.92 EPS for the quarter, hitting analysts' consensus estimates of $0.92. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. The company had revenue of $11.87 billion for the quarter. Equities analysts anticipate that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.